Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 1574 Records) |
Query Trace: Brca[original query] |
---|
Comparing Prognosis for BRCA1, BRCA2, and Non-BRCA Breast Cancer. Cancers 2023 12 15 (23): . Pedro Antunes Meireles, Sofia Fragoso, Teresa Duarte, Sidónia Santos, Catarina Bexiga, Priscila Nejo, Ana Luís, Beatriz Mira, Isália Miguel, Paula Rodrigues, Fátima V |
Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis. Targeted oncology 2023 12 . Brigida Anna Maiorano, Ugo De Giorgi, Elena Verzoni, Evaristo Maiello, Giuseppe Procopio, Vincenza Conteduca, Massimo Di Maio, |
Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations. Clinica chimica acta; international journal of clinical chemistry 2023 12 552 117695. Mar Infante, Mónica Arranz-Ledo, Enrique Lastra, Amaya Olaverri, Raquel Ferreira, Marta Orozco, Lara Hernández, Noemí Martínez, Mercedes Dur |
Presence of crown-like structures in breast adipose tissue; differences between healthy controls, BRCA1/2 gene mutation carriers and breast cancer patients. Breast cancer research and treatment 2023 12 . Mieke C Zwager, Iris Holt-Kedde, Hetty Timmer-Bosscha, Geertruida H de Bock, Paul M N Werker, Carolien P Schröder, Bert van der Vegt, Marlous Arjaa |
Novel disulfidptosis-derived gene blueprint stratifying patients with breast cancer. Environmental toxicology 2023 12 . Xiaojiang Tang, Baohua Ping, Yang Liu, Yuhui Zh |
Germline BRCA2 Pathogenic Variant in Primary Breast Cancer of a Down Syndrome Individual. The American journal of case reports 2023 12 24 e942208. Tsuyoshi Shinohara, Takuo Asoda, Yuta Nakano, Hiroyuki Yamada, Yoshiro Fujimo |
Platinum-free Interval May Predict Duration of Maintenance Bevacizumab and Survival in Platinum-sensitive Recurrent Ovarian Cancer. In vivo (Athens, Greece) 2023 12 38 (1): 467-473. Soo Hyun Oh, Soo Jin Park, Seungmee Lee, Seungho Lee, Hee Seung K |
FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 12 JCO2301868. Jaleh Fallah, Jianjin Xu, Chana Weinstock, Michael H Brave, Erik Bloomquist, Mallorie H Fiero, Timothy Schaefer, Anand Pathak, Abdelrahmman Abukhdeir, Vishal Bhatnagar, Haw-Jyh Chiu, Tiffany Ricks, Christy John, Salaheldin Hamed, Christal Lee, William F Pierce, Shyam Kalavar, Reena Philip, Shenghui Tang, Laleh Amiri-Kordestani, Richard Pazdur, Paul G Kluetz, Daniel Suzm |
ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network. Aging 2023 12 15 . Hongyan Qian, Rui Ji, Cheng Shen, Yinze Wei, Chenyi Sheng, Qichao Ni, Jing Pan, Yifan Chi, Huan You, Ying Miao, Minxin Shi, Xianghua Huang, Aiguo Sh |
Cerebellar metastasis of ovarian cancer: a case report. Journal of medical case reports 2023 12 17 (1): 553. Eleonora Cabitza, Marta Pirola, Cinzia Baldessari, Giuditta Bernardelli, Elena Zunarelli, Stefania Pipitone, Maria Giuseppa Vitale, Cecilia Nasso, Eleonora Molinaro, Marco Oltrecolli, Elisa D'Agostino, Vincenzo Dario Mandato, Andrea Palicelli, Massimo Dominici, Roberto Sabbati |
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival. Gynecologic oncology 2023 12 180 35-43. Ryan M Kahn, Pier Selenica, Thomas Boerner, Kara Long Roche, Yonghong Xiao, Tiffany Y Sia, Anna Maio, Yelena Kemel, Margaret Sheehan, Erin Salo-Mullen, Kelsey E Breen, Qin Zhou, Alexia Iasonos, Rachel N Grisham, Roisin E O'Cearbhaill, Dennis S Chi, Michael F Berger, Ritika Kundra, Nikolaus Schultz, Lora H Ellenson, Zsofia K Stadler, Kenneth Offit, Diana Mandelker, Carol Aghajanian, Dmitriy Zamarin, Paul Sabbatini, Britta Weigelt, Ying L L |
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast cancer research and treatment 2023 12 . Judith Balmaña, Peter A Fasching, Fergus J Couch, Suzette Delaloge, Intidhar Labidi-Galy, Joyce O'Shaughnessy, Yeon Hee Park, Andrea F Eisen, Benoit You, Hughes Bourgeois, Anthony Gonçalves, Zoe Kemp, Angela Swampillai, Tomasz Jankowski, Joo Hyuk Sohn, Elena Poddubskaya, Guzel Mukhametshina, Sercan Aksoy, Constanta V Timcheva, Tjoung-Won Park-Simon, Antonio Antón-Torres, Ellie John, Katherine Baria, Isabel Gibson, Karen A Gelmon, |
Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer. Gynecologic oncology 2023 12 181 33-39. Ji Hyun Kim, Se Ik Kim, Eun Young Park, Eun Taeg Kim, Hyesu Kim, Sangeon Kim, Sang-Yoon Park, Myong Cheol L |
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer 2023 12 . Fatma Nihan Akkoc Mustafayev, Mihir Amitabh Shukla, Amanda Lanier, Denái R Milton, Angelica M Gutierrez, Stephen K Gruschkus, John E Lewis, Rashmi K Murthy, Banu K Ar |
Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden. PharmacoEconomics - open 2023 12 . Maria Polyzoi, Mattias Ekman, Anja Reithmeier, Johanna Jacob, Emma Karlsson, Evelina Bertranou, Barbro Linderholm, Robert Hett |
Identification and validation of Golgi apparatus-related signature for predicting prognosis and immunotherapy response in breast cancer. Journal of cancer research and clinical oncology 2024 2 150 (2): 61. Xin Chen, Pengting Tang, Ying Kong, Deqin Chen, Kejun Ta |
Risk factors for ovarian cancer by BRCA status: a collaborative case-only analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2024 2 . Kate Gersekowski, Renhua Na, Kathryn Alsop, Rachel Delahunty, Ellen L Goode, Julie M Cunningham, Stacey J Winham, Paul D P Pharoah, Honglin Song, Penelope M We |
Genetic contribution of breast cancer genes in women of black African origin. Frontiers in genetics 2024 1 14 1302645. Rokhaya Ndiaye, Jean Pascal Demba Diop, Ahmadou Dem, Alioune Die |
Copper Chaperone for Superoxide Dismutase Subtypes as a Prognostic Marker in Luminal B Breast Cancer. Clinical Medicine Insights. Oncology 2024 1 18 11795549231219239. Yanping Li, Wenfei Du, Rui Yang, Xiaonan Wei, Haibin Li, Xiaoyuan Zha |
Combinational use of trabectedin and pegylated liposomal doxorubicin for recurrent ovarian cancer: a meta-analysis of phase III randomized controlled trials. American journal of translational research 2024 1 15 (12): 6675-6689. Chao Li, Siyi Qiao, Min Kang, Xiaofeng Gao, Zhiru |
A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations. Diagnostic pathology 2024 1 19 (1): 9. Anne Vogel, Anna Haupts, Michael Kloth, Wilfried Roth, Nils Hartma |
BRCA 1/2 mutations and risk of uterine cancer: a systematic review and meta-analysis. BMC genomic data 2024 1 25 (1): 13. Faezeh Zakerinasab, Qumars Behfar, Reza Parsaee, Reza Hossein Zadeh, Elaheh Foroughi, Amirhesam Amirbeik, Ghazalehsadat Ahma |
Outcomes of BRCA pre-implantation genetic testing according to the parental mutation origin: a cohort study. Reproductive biology and endocrinology : RB&E 2024 1 22 (1): 8. Ilana Weizel, Tal Shavit, Yulia Shuli, Chana Adler Lazarovich, Rivka Halevi, Tal Ben Ari, Shira Yaacobi-Artzi, Yaakov Bentov, Baruch Feldman, Anat Hershko Kleme |
BRCA mutation status and pathological characterization of breast cancer in Zhoushan Islands, China. The Journal of international medical research 2024 1 52 (1): 3000605231223426. Shuhui Bao, Nini Sun, Yaling Li, Jiaojie Shu, Jing Xu, Yong Zhang, Xia Q |
A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China. Frontiers in oncology 2024 1 13 1300199. Jinghong Chen, Mengpei Zhang, Kemin Li, Yuanqiong Duan, Xiaojuan Lin, Lan Zhong, Qintong Li, Rutie Y |
Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study. Breast cancer research : BCR 2024 1 26 (1): 14. Eunhye Kang, Ji-Jung Jung, Changjin Lim, Hong-Kyu Kim, Han-Byoel Lee, Wonshik Han, Hyeong-Gon Mo |
BRCA mutation patients: are there other predisposing factors for ovarian cancer occurrence? A multicentre retrospective study. Gynecologic and obstetric investigation 2024 1 . Vera Loizzi, Michele Mongelli, Francesca Arezzo, Isabella Romagno, Gerardo Cazzato, Ondina Popescu, Francesco Legge, Paolo Trerotoli, Erica Silvestris, Anila Kardhashi, Gennaro Corm |
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 1 . Tira J Tan, Sarah Sammons, Young-Hyuck Im, Lilin She, Kelly Mundy, Robert Bigelow, Tiffany A Traina, Carey Anders, Joe Yeong, Ezequiel Renzulli, Sung-Bae Kim, Rebecca De |
Association Between Germline BRCA1/2 Gene Variants and Clinicopathological Features of Ovarian Cancer. International journal of general medicine 2024 1 17 75-84. Yu Luo, Ru Pan, Hui Rao, Xing Chen, Haikun Ya |
Radiation-Induced Lymphopoenia and Treatment Outcome in Hereditary Breast Cancer Patients. Folia biologica 2024 1 69 (3): 91-98. So?a Argalácsová, ?udmila K?ížová, Martin Mat?j?, Dominika Svobodová, Michal Vo? |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 18, 2024
- Content source: